文献速递肿瘤 PET/CT

肝细胞癌免疫治疗超进展的FDG PET表现

FDG PET Findings of Hyperprogression During Immunotherapy in a Patient With Hepatocellular Carcinoma.
PubMed 文献 · Clin Nucl Med · 2020-01-01

超进展表现为免疫治疗后加速进展并导致更差结局,早期难以识别,随访评估一旦确诊应立即停止免疫治疗。

要点

  • 免疫治疗可致部分患者超进展,表现为治疗后加速进展、结局更差。
  • 随访确诊超进展后应立即停止免疫治疗。

临床怎么用

  • 超进展早期难以识别,随访评估确诊后应立即停止免疫治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although immunotherapy is a successful approach in oncology, it might be detrimental to some patients. In the condition of hyperprogression, patients experience accelerated progression after immunotherapy, resulting in a worse outcome. Hyperprogression may be difficult to be identified in the early stage. Once the diagnosis is confirmed in the follow-up evaluation, the immunotherapy should be stopped immediately. In this case, we report a hyperprogression patient during combined immunotherapy toward metastatic hepatocellular carcinoma observed by serial F-FDG PET.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wang J, Wang X, Yang X, et al. FDG PET Findings of Hyperprogression During Immunotherapy in a Patient With Hepatocellular Carcinoma. Clin Nucl Med. 2020. PMID: 31789917. doi:10.1097/RLU.0000000000002849

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。